RxDoctor Payments Data

Gloria Anding, MD

Internal Medicine · Euless, TXNPI 1245235621

Payments from drug & device makers

$14,912in general payments, 2019–2025

Across 899 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$14,880100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)99$1,451
AstraZeneca77$1,390
Boehringer Ingelheim72$1,311
Novo Nordisk95$1,279
Lilly USA, LLC72$1,049
GSK57$1,026
Pfizer40$587
Bayer34$552
Astellas Pharma US Inc26$530
Amarin Pharma, Inc.24$475
Johnson & Johnson22$474
Amgen27$463
Abbott22$442
Takeda Pharmaceuticals U.S.A., Inc.26$395
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$263
Merck17$240
Exact Sciences11$235
Novartis15$223
E.r. Squibb & Sons, L.L.C.9$151
Sanofi-aventis U.S. LLC9$141
Ironwood Pharmaceuticals, Inc9$136
Tris Pharma Inc7$135
Biohaven Pharmaceutical Holding Company Ltd.6$117
Kowa Pharmaceuticals America, Inc.8$114
Dexcom, Inc.7$108
Azurity Pharmaceuticals, Inc.5$100
Biogen6$100
Genentech USA, Inc.6$93
Alnylam Pharmaceuticals Inc.4$80
Eisai Inc.5$79
Nestle Healthcare Nutrition Inc.5$77
Sumitomo Pharma America, Inc.5$76
Orexo US, Inc.5$76
Arbor Pharmaceuticals, Inc.5$71
IBSA Pharma Inc.4$71
Avvisto Therapeutics, LLC4$69
Otsuka America Pharmaceutical, Inc.4$67
Aimmune Therapeutics, Inc.3$58
Inspire Medical Systems, Inc.1$54
Antares Pharma, Inc.3$46
Corcept Therapeutics2$44
Lundbeck LLC2$44
Teva Pharmaceuticals USA, Inc.2$39
Idorsia Pharmaceuticals US Inc2$39
Seqirus USA Inc2$35
Supernus Pharmaceuticals, Inc.2$33
Vertical Pharmaceuticals, LLC1$24
Pharming Healthcare, Inc.1$24
Sunovion Pharmaceuticals Inc.1$23
VBI Vaccine (delaware) Inc.1$21
Biohaven Pharmaceuticals, Inc.1$19
Amneal Pharmaceuticals LLC1$18
Sanofi Pasteur Inc.1$17
Radius Health, Inc.1$17
Hikma Pharmaceuticals USA1$15
Halozyme Inc1$15
Xeris Pharmaceuticals, Inc.1$15
Boston Scientific1$14
Neuronetics, Inc.1$14
Tolmar, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,912 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$113,554
Medicare patients
262
Services billed
2,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$102,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$96,097
JardianceEmpagliflozin76$91,501
EliquisApixaban49$56,026
MounjaroTirzepatide41$44,708
FarxigaDapagliflozin Propanediol39$37,367
JanuviaSitagliptin Phosphate28$28,557
TrulicityDulaglutide20$20,628
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$20,235
Repatha SureclickEvolocumab32$19,651
VascepaIcosapent Ethyl33$16,974
Breo ElliptaFluticasone/Vilanterol22$15,134
XareltoRivaroxaban16$14,034
LinzessLinaclotide11$12,558
PremarinEstrogens, Conjugated26$11,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$1,026$133,674158 claims
Novo NordiskOzempic$1,279$102,02384 claims
Boehringer IngelheimJardiance$1,311$91,50176 claims
PfizerEliquis, Premarin$587$67,82775 claims
Lilly USA, LLCMounjaro, Trulicity$1,049$65,33561 claims
AstraZenecaFarxiga, Symbicort$1,390$47,81670 claims
MerckJanuvia$240$28,55728 claims
AbbVieLinzess, Synthroid$1,451$17,19394 claims
Johnson & JohnsonXarelto$474$14,03416 claims
Astellas Pharma US IncMyrbetriq$530$6,65113 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$6,063743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Euless

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →